MSD’s Keytruda receives green light from NICE for NHS use
October 12, 2015Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer
The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …
Novartis psoriasis drug shows three-year efficacy
October 12, 2015Cosentyx, EADV, Novartis, Secukinumab, psoriasis
Novartis has announced new trial data confirming the efficacy of Cosentyx in patients with moderate-to-severe plaque psoriasis. The results of …
How can pharma succeed in emerging markets?
October 10, 2015Sales and Marketing GSK, Pfizer
In recent years, the major pharma companies have been forced to react to the maturation and cost-cutting, plus regulatory pressures, …
Biogen reports on Tecfidera multiple sclerosis clinical trials
October 9, 2015Research and Development
Biogen has presented data demonstrating the efficacy and safety of Tecfidera (dimethyl fumarate) across a broad range of people with …
Almirall presents new data on cannabinoid-based MS treatment
October 9, 2015Research and Development Almirall, multiple sclerosis
Almirall has presented new clinical evidences of Sativex, the only medicine derived from cannabinoids to treat spasticity symptoms in MS, …
EMA appoints Guido Rasi as executive director
October 9, 2015Medical Communications, Sales and Marketing EMA, Guido Rasi
The European Medicines Agency’s (EMA’s) Management Board has nominated Professor Guido Rasi as the Executive Director of the Agency. The …
Oncology groups and doctors fight for lower-priced cancer treatments
October 9, 2015Medical Communications, Research and Development, Sales and Marketing
Oncology groups such as the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) are working …
Sanofi looks to increase productivity in France by 25%
October 9, 2015Manufacturing and Production, Medical Communications Sanofi
Sanofi is looking for a deal with unions in order to boost productivity by 20-25% at French plants over three …
Merck announces positive Elbasvir/Grazoprevir trial results
October 9, 2015Research and Development
Merck has announced the publication of results from C-SURFER, the first Phase III clinical trial to investigate an all-oral, ribavirin-free …
AstraZeneca’s Moventig now available through NHS
October 9, 2015Medical Communications, Research and Development, Sales and Marketing AstraZeneca, moventig
AstraZeneca has announced that Moventig (naloxegol) has been made available for adult patients with opioid-induced constipation (OIC) in England and …
Taking on IFP, COPD and severe asthma: ERS 2015 roundup
October 9, 2015Medical Communications, Research and Development
Leading pharmaceutical companies, physicians, healthcare professionals, scientists, respiratory experts, and of course the media, including Pharmafocus, gathered in Amsterdam at the …
Ovid Therapeutics appoints Dr Jerome B. Zeldis to Its Scientific Advisory Board
October 9, 2015Medical Communications
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, has …
Positive late-stage results for Genentech’s ocrelizumab in different forms of MS
October 8, 2015Research and Development ECTRIMS, Genentech, MS, Roche, multiple sclerosis, ocrelizumab
Roche’s biotech arm Genentech has presented ‘transformative’ data at an international multiple sclerosis conference on its investigational drug ocrelizumab. Ocrelizumab …
Innovative pipeline can transform obesity treatment, says GBI Research
October 8, 2015Research and Development obesity
While the current obesity treatment market has a high level of unmet need, the therapeutic landscape could be transformed by …
Simple blood test can accurately predict imminent heart attacks
October 8, 2015Research and Development NHS, heart attack
A simple blood test which predicts whether a patient suffering chest pains will have a heart attack has the potential to save …
Novartis looks to new measure of Gilenya outcomes
October 8, 2015Research and Development fingolimod, gilenya, multiple sclerosis, relapsing multiple sclerosis
Novartis says a new analysis from two Phase III trials reinforces the long-term efficacy profile of its MS treatment Gilenya. …
UCB plots new Vimpat submissions after positive monotherapy results
October 8, 2015Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat
A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments. …
Genzyme’s Lemtrada shows five-year efficacy in extended trials
October 8, 2015Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
Infectious diseases dominate Nobel Prize awards for medicine
October 8, 2015Manufacturing and Production, Research and Development Nobel Prize, artemisinin, ivermectin, malaria, mectizan, river blindness
Pharma researchers have been awarded the 2015 Nobel Prize for their work on a river blindness treatment, along with work …
Multiple Sclerosis treatment will be a $20bn market by 2024
October 7, 2015Research and Development multiple sclerosis
The value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
